2023 World Conference on Lung Cancer (Posters)-EP13.06. Phase II Study of Pembrolizumab, Plinabulin plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer

EP13.06. Phase II Study of Pembrolizumab, Plinabulin plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

This study aims to evaluate the efficacy and safety of pembrolizumab, plinabulin, etoposide, and platinum as the first-line therapy for patients with extensive-stage small-cell lung cancer (ES-SCLC). Previous studies have shown that the addition of immune checkpoint inhibitors (ICIs) to etoposide and platinum improves progression-free and overall survival for ES-SCLC patients. Moreover, pembrolizumab in combination with etoposide and platinum has been found to significantly improve progression-free survival in these patients. However, the prognosis for ES-SCLC remains poor.<br /><br />Plinabulin, a synthetic analogue derived from a marine fungus, has immune-enhancing effects by stimulating dendritic cells and preventing chemotherapy-induced neutropenia. It is hypothesized that the combination of plinabulin and immunochemotherapy may have a synergistic effect in treating ES-SCLC.<br /><br />The study is an open-label, single-arm, phase II trial aiming to enroll approximately 45 patients with histologically confirmed ES-SCLC. Eligible patients must be at least 18 years old, newly diagnosed with ES-SCLC, and have an Eastern Cooperative Oncology Group performance status of 0-1. Patients with prior systemic therapy for SCLC are excluded. <br /><br />The treatment regimen consists of pembrolizumab, etoposide, platinum, and plinabulin. During the first four cycles, patients will receive pembrolizumab, etoposide, platinum, and plinabulin. In subsequent cycles, patients will continue to receive pembrolizumab and plinabulin. The primary endpoint of the study is the progression-free survival rate at 12 months. Secondary endpoints include objective response rate, duration of response, median progression-free survival, overall survival, and safety. <br /><br />The study has been approved by the hospital institutional review board and will provide valuable insights into the efficacy and safety of this combination therapy for the treatment of ES-SCLC.

Asset Subtitle

Xiaorong Dong

Meta Tag

Speaker Xiaorong Dong

Topic SCLC & Neuroendocrine Tumors: Preclinical

Keywords

pembrolizumab

plinabulin

etoposide

platinum

first-line therapy

extensive-stage small-cell lung cancer

immune checkpoint inhibitors

progression-free survival

synergistic effect

phase II trial